Blog icon

7 December 2023 News Release

Addressing global health challenges, championing sustainability through circularity, and advancing the realms of advanced manufacturing, are some of the areas of innovation teams selected for the next stage of CSIRO’s ON Accelerate program are advancing. 

Australia’s national science agency, CSIRO, has revealed the project teams forming part of the program's next phase to develop high-potential innovative ventures for launch into the Australian market.

ON Accelerate is a structured accelerator for entrepreneurial researchers, providing them the tools and resources to translate their great ideas into real-world impact as a startup.  

The program provides researchers access to a network of industry experts and investors, enabling them to refine and validate their ideas for commercial success, ultimately helping them secure funding and build a company. 

CSIRO Chief Executive, Doug Hilton said the ON program has reshaped Australian innovation since its 2015 launch. 

“ON Accelerate is about creating national benefits for Australia by giving researchers the skills they need to navigate their ideas along the often-fraught road between the lab and the market,” Dr Hilton said. 

“Research commercialisation, science entrepreneurship and technical collaboration are all critical skills for Australia’s future and the ON program is equipping the next generation of innovators with the skills they need to make a difference for our future.” 

The teams moving to the next stage of ON Accelerate include: 

  • Jessie Technology, from the Australian Catholic University and supported by Microsoft, has developed an autonomous data entry technology that enhances the quality of care for aged care residents by reducing the time needed for workers to input data and compliance documentation while also enhancing workforce retention and meeting aged care provider compliant requirements. 
  • ErythroSight, also from the Australian National University, is tackling a major challenge in treating retinal diseases, such as age-related macular degeneration, by developing a novel therapeutic from patients' own red blood cells.
  • AquaTone Solutions, hailing from Griffith University, is harnessing the convergence of life sciences and machine learning to pioneer intelligent prawn farm management and deliver timely alerts to stakeholders on a local and global scale.
  • Infinite Bioworks, from James Cook University, is a startup specialising in advanced starter cells to fuel the future bio-revolution. The team’s goal is to partner with customers to develop advanced materials and ingredients that positively impact the planet.
  • Originating out of the University of Newcastle, Wild Yeast Zoo’s technology leverages native yeast strains from Australia's diverse ecosystems, isolating and characterising them to unlock novel pathways for industries like brewing, baking, pharmaceuticals, and biofuels.
  • Plasmid Therapy is a joint effort team from The Westmead Institute for Medical Research and The University of Sydney. The team is working on a technology that addresses the global threat of antimicrobial-resistant (AMR) infections. Removing AMR genes from bacteria and keeping them out with an affordable and safe oral solution makes common treatments safer and more effective.
  • Environmental Measurement Unit Systems or EMUS, from The University of Sydney deliver advanced heat stress management systems for athletes that in real-time optimises performance and keeps players safe.
  • From the University of Western Australia and partners, Cytophenix’s patented technology is an AI-boosted antimicrobial susceptibility test (AST), delivering clinically actionable evidence of antibiotic effectiveness in 3-5 hours, compared to the current 2-5 days.
  • Continuous3D, another team from CSIRO, offers a fully automated solution for efficiently repairing critical metal components using sensors and advanced algorithms, significantly reducing robot program development time from weeks to minutes.
  • Dragonfly Thinking, from Australian National University, helps users navigate complexity using structured analytic techniques and AI. Through Multi-Lens Analysis (MLA.ai) and trademarked Risk, Reward, and Resilience Framework (RRR.ai), Dragonfly Thinking seeks to show the world from different lenses, integrate diverse views, and make informed predictions for better decision-making.

In February, the teams drawn from universities and research institutions nationwide will embark on an intensive immersion week, setting the stage for a rigorous three-month ON Accelerate program.

They will collaborate with a carefully selected group of experts, engaging in personalised coaching and development plans.

The program aims to provide the cohort with comprehensive insights to transform their projects into market-ready ventures.

Teams that complete the full ON Accelerate program will graduate with a robust business model, a well-defined route to commercialisation, and be viable startups.

For additional images of participating ON Accelerate 8 teams, please click here.

Fast Facts:

  • The project teams forming part of ON Accelerate program's next phase to develop high-potential innovative ventures for launch into the Australian market.
  • More than 4800 researchers from over 1200 teams from 52 Australian universities and publicly funded research organisations have developed their research translation skills through ON.
  • Since the program was established, ON alumni have formed 70 new companies, employed more than 600 people and raised more than $311 million in investment capital.
  • Over $305 million in commercialisation grants have also been secured by ON alumni.

For more images of the On Accelerate 8 teams.

Updated on February 13, 2024.

Images

Jessie Technology, from the Australian Catholic University and supported by Microsoft, has developed an autonomous data entry technology that enhances the quality of care for aged care residents by reducing the time needed for workers to input data and compliance documentation while also enhancing workforce retention and meeting aged care provider compliant requirements.
From the University of Western Australia and partners, Cytophenix’s patented technology is an AI-boosted antimicrobial susceptibility test (AST), delivering clinically actionable evidence of antibiotic effectiveness in 3-5 hours, compared to the current 2-5 days.
ErythroSight, also from the Australian National University, is tackling a major challenge in treating retinal diseases, such as age-related macular degeneration, by developing a novel therapeutic from patients' own red blood cells.

Contact us

Find out how we can help you and your business. Get in touch using the form below and our experts will get in contact soon!

CSIRO will handle your personal information in accordance with the Privacy Act 1988 (Cth) and our Privacy Policy.


First name must be filled in

Surname must be filled in

I am representing *

Please choose an option

Please provide a subject for the enquriy

0 / 100

We'll need to know what you want to contact us about so we can give you an answer

0 / 1900

You shouldn't be able to see this field. Please try again and leave the field blank.